Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published online before print December 28, 2005, doi:10.1212/01.wnl.0000195888.51845.80)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow CME: Take the course for this article:
Volume 66, Number 3, February 14, 2006
Right arrow Data Supplement
Right arrow Polish Translation
Right arrow All Versions of this Article:
01.wnl.0000195888.51845.80v1
66/3/354    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Received June 30, 2005
Accepted October 24, 2005

Seizure control and treatment in pregnancy. Observations from the EURAP Epilepsy Pregnancy Registry

The EURAP Study Group

Abstract-- Objective: To analyze seizure control and treatment in pregnant women with epilepsy. Methods: Seizure control and treatment were recorded prospectively in 1,956 pregnancies of 1,882 women with epilepsy participating in EURAP, an international antiepileptic drugs (AEDs) and pregnancy registry. Results: Of all cases, 58.3% were seizure-free throughout pregnancy. Occurrence of any seizures was associated with localization-related epilepsy (OR: 2.5; 1.7 to 3.9) and polytherapy (OR: 9.0; 5.6 to 14.8) and for tonic-clonic seizures, with oxcarbazepine monotherapy (OR: 5.4; 1.6 to 17.1). Using first trimester as reference, seizure control remained unchanged throughout pregnancy in 63.6%, 92.7% of whom were seizure-free during the entire pregnancy. For those with a change in seizure frequency, 17.3% had an increase and 15.9% a decrease. Seizures occurred during delivery in 60 pregnancies (3.5%), more commonly in women with seizures during pregnancy (OR: 4.8; 2.3 to 10.0). There were 36 cases of status epilepticus (12 convulsive), which resulted in stillbirth in one case but no cases of miscarriage or maternal mortality. AED treatment remained unchanged in 62.7% of the pregnancies. The number or dosage of AEDs were more often increased in pregnancies with seizures (OR: 3.6; 2.8 to 4.7) and with monotherapy with lamotrigine (OR: 3.8; 2.1 to 6.9) or oxcarbazepine (OR: 3.7; 1.1 to 12.9). Conclusions: The majority of patients with epilepsy maintain seizure control during pregnancy. The apparently higher risk of seizures among women treated with oxcarbazepine and the more frequent increases in drug load in the oxcarbazepine and lamotrigine cohorts prompts further studies on relationships with pharmacokinetic changes. Risks associated with status epilepticus appear to be lower than previously reported.




This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
E. Nordmo, L. Aronsen, K. Wasland, L. Smabrekke, and S. Vorren
Severe Apnea in an Infant Exposed to Lamotrigine in Breast Milk
Ann. Pharmacother., November 1, 2009; 43(11): 1893 - 1897.
[Abstract] [Full Text] [PDF]


Home page
PNHome page
J. J Craig and S. J Hunt
Treating women with juvenile myoclonic epilepsy
Practical Neurology, October 1, 2009; 9(5): 268 - 277.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
H. Chen, K. Yang, S. Choi, J. H. Fischer, and H. Jeong
Up-Regulation of UDP-Glucuronosyltransferase (UGT) 1A4 by 17{beta}-Estradiol: A Potential Mechanism of Increased Lamotrigine Elimination in Pregnancy
Drug Metab. Dispos., September 1, 2009; 37(9): 1841 - 1847.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
Y.-H. Chen, H.-Y. Chiou, H.-C. Lin, and H.-L. Lin
Affect of Seizures During Gestation on Pregnancy Outcomes in Women With Epilepsy
Arch Neurol, August 1, 2009; 66(8): 979 - 984.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
C. L. Harden, J. Hopp, T. Y. Ting, P. B. Pennell, J. A. French, W. A. Hauser, S. Wiebe, G. S. Gronseth, D. Thurman, K. J. Meador, et al.
Practice Parameter update: Management issues for women with epilepsy--Focus on pregnancy (an evidence-based review): Obstetrical complications and change in seizure frequency: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society
Neurology, July 14, 2009; 73(2): 126 - 132.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
K. J. Meador, P. B. Pennell, C. L. Harden, J. C. Gordon, T. Tomson, P. W. Kaplan, G. L. Holmes, J. A. French, W. A. Hauser, P. G. Wells, et al.
Pregnancy registries in epilepsy: A consensus statement on health outcomes
Neurology, September 30, 2008; 71(14): 1109 - 1117.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
P. B. Pennell, L. Peng, D. J. Newport, J. C. Ritchie, A. Koganti, D. K. Holley, M. Newman, and Z. N. Stowe
Lamotrigine in pregnancy: Clearance, therapeutic drug monitoring, and seizure frequency
Neurology, May 27, 2008; 70(22_Part_2): 2130 - 2136.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
G. Montouris
Importance of monotherapy in women across the reproductive cycle
Neurology, December 11, 2007; 69(24_suppl_3): S10 - S16.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
T. Tomson and V. Hiilesmaa
Epilepsy in pregnancy
BMJ, October 13, 2007; 335(7623): 769 - 773.
[Full Text] [PDF]


Home page
NeurologyHome page
J. Christensen, A. Sabers, and P. Sidenius
Oxcarbazepine concentrations during pregnancy: A retrospective study in patients with epilepsy
Neurology, October 24, 2006; 67(8): 1497 - 1499.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by AAN Enterprises, Inc.